Anti-Cancer Drugs

4.5k papers and 82.9k indexed citations i.

About

The 4.5k papers published in Anti-Cancer Drugs in the last decades have received a total of 82.9k indexed citations. Papers published in Anti-Cancer Drugs usually cover Oncology (2.1k papers), Molecular Biology (2.0k papers) and Pulmonary and Respiratory Medicine (906 papers) specifically the topics of Cancer Treatment and Pharmacology (478 papers), Cancer therapeutics and mechanisms (477 papers) and Colorectal Cancer Treatments and Studies (373 papers). The most active scholars publishing in Anti-Cancer Drugs are Ruth Duncan, Jos H. Beijnen, Jaap Verweij, Vincent T. DeVita, S A Rosenberg, S Hellman, Howard L. McLeod, Daniel Morgensztern, Richard L. Momparler and Francis Loor.

In The Last Decade

Fields of papers published in Anti-Cancer Drugs

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Anti-Cancer Drugs. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Anti-Cancer Drugs

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Anti-Cancer Drugs. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Anti-Cancer Drugs with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025